Skip to main content
. 2023 Jan 1;19(1):34–49. doi: 10.7150/ijbs.72381

Figure 4.

Figure 4

KMT2B promotes CC growth and angiogenesis in vivo. (A) Tumor growth curves of HeLa-VC and HeLa-KMT2B groups. The volumes of subcutaneous xenografts were measured during an 18-day period after tumor cell inoculation. (n = 5 for each group). (B) Representative images of subcutaneous xenografts tumors formed by HeLa-VC and HeLa-KMT2B cells. (C) Tumor weights of each group. (D) The representative hematoxylin-eosin (H&E) staining and the representative immunohistochemical staining of Ki67 and CD-31 of the subcutaneous tumors. Scale bars, 100 µm. (E) IHC analysis for Ki-67 expression was performed in tumors harvested from xenografts, and percents of the Ki-67 positive cells were quantified. (n = 6 for each group). (F) Number of microvessels was counted in each group. (n = 6 for each group). (G) Tumor growth curves of HeLa-SC and HeLa-KMT2BKO groups. The volumes of subcutaneous xenografts were measured during a 21-day period after tumor cell inoculation. (n = 6 for each group). (H) Representative images of subcutaneous xenografts tumors formed by HeLa-SC and HeLa-KMT2BKO cells. (I) Tumor weights of each group. (J) The representative H&E staining and the representative immunohistochemical staining of Ki67 and CD-31 of the subcutaneous tumors. Scale bars, 100 µm. (K) IHC analysis for Ki-67 expression was performed in tumors harvested from xenografts, and percent of the Ki-67 positive cells were quantified. (n = 6 for each group). (L) Number of microvessels was counted in each group. (n = 6 for each group). Data represent the mean ± SD. Statistical significance was determined by student's t test. *, p < 0.05, **, p < 0.01.